How we grade evidence
- L1 Multiple randomized controlled trials with consistent effect; systematic reviews support the intervention.
- L2 At least one RCT plus larger case series; effect direction consistent but magnitude debated.
- L3 Case series, small pilots, animal data extrapolated; plausible but unproven at scale.
- L4 Testimonial, marketing, or fringe-diagnosis claims without peer-reviewed evidence of benefit.
What frozen shoulder actually is
Adhesive capsulitis is inflammation and fibrosis of the glenohumeral joint capsule, causing progressive pain and loss of both active and passive range of motion — external rotation is usually the first and worst-affected direction. The classic clinical course runs 12–24 months through freezing (painful, losing motion), frozen (stiff, less painful), and thawing (gradual motion return) phases. Most cases resolve, but the timeline is punishing and residual limitation is not uncommon.
Standard first-line treatment is physical therapy plus one or a combination of: intra-articular corticosteroid injection, hydrodilatation (capsular distension with saline under imaging), or oral analgesics. Manipulation under anesthesia and arthroscopic capsular release are reserved for cases that fail conservative care.
Where cell therapy has been tried
The regenerative literature for adhesive capsulitis is thin. A handful of small case series report intra-articular MSC or bone-marrow-concentrate injections combined with capsular distension, with modest reported gains in range of motion beyond distension alone. There are no adequately-powered randomized trials establishing that MSCs add meaningful benefit over hydrodilatation plus PT, which is one of the better-supported interventions for this condition.
PRP has slightly more published data than cell therapy and has shown mixed results — some trials favor it over saline, others show no difference.
Where cell therapy might make sense
- Recurrent adhesive capsulitis in the same shoulder after prior conservative treatment.
- Diabetic adhesive capsulitis, which typically has a longer, more severe course and worse steroid response.
- Patients unwilling or unable to have steroid injections.
Where it does not
A first-episode adhesive capsulitis in a non-diabetic patient during the freezing phase is best managed with the mainstream stepwise approach. Hydrodilatation is inexpensive, well-supported, and often dramatically effective. Skipping it to try cell therapy first is not supported by the data.
The rehabilitation half matters more than the injection
Whatever gets injected into a frozen shoulder, the recovery is driven by disciplined range-of-motion work. A properly-guided PT program with home exercises is not optional — it is the treatment. Clinics that inject and send you home with a pamphlet are underselling how much active work this condition requires.
If cell therapy helps at all, expect gradual gains over 8–16 weeks, not overnight motion return. Frozen shoulder has a natural history of eventual improvement — separating treatment effect from natural course is why single-arm case series are hard to interpret for this condition.
Regulatory status — Adhesive capsulitis
Frozen shoulder that hasn't responded to standard care?
Send us your imaging and treatment history on WhatsApp. We'll help you evaluate options honestly.
Ask a question on WhatsApp